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Do Prostaglandins Have a Salutary Role in Skeletal Muscle
Ischaemia–reperfusion Injury?
T. E. Rowlands, M. J. Gough and S. Homer-Vanniasinkam*
Vascular Surgical Unit, The General Infirmary at Leeds, U.K.
Objectives: the effects of prostaglandins (PG) E1, E2, and the prostacyclin analogue iloprost with and without the addition
of free-radical scavengers catalase and superoxide dismutase on gastrocnemius blood flow and oedema were studied in a
rodent model of hindlimb ischaemia–reperfusion.
Methods: male Sprague–Dawley rats underwent 6-h hindlimb ischaemia with 4-h reperfusion. Prostaglandins were
infused prior to reperfusion and their effects on limb blood flow and oedema examined.
Results: control animals exhibited a triphasic pattern of muscle blood flow during reperfusion compared to normal
animals. PGE1 did not abolish low reflow at 10 min, relative reperfusion was preserved but reperfusion injury was
abolished at 120 min. Muscle blood flow was increased at 240 min compared to controls. Increased limb swelling was
also seen. Addition of free-radical scavengers caused the abolition of low reflow. Similar results were seen with iloprost.
PGE2 abolished low reflow at 10 min and increased perfusion at 120 min but did not prevent reperfusion injury at 240
min.
Conclusions: PGE1 and iloprost enhance muscle blood flow at 4-h reperfusion, though neither abolishes low reflow; PGE2
improved flow at 10 and 120 min but not after 240 min. This study demonstrates a potentially beneficial role for
prostaglandins in improving muscle blood flow in skeletal muscle ischaemia–reperfusion injury.
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Introduction a variety of cells including endothelial cells, smooth-
muscle cells, leucocytes, platelets and fibroblasts. Pro-
Reperfusion injury involves microcirculatory collapse stanoids known to be biologically active in the cir-
culation include prostaglandins E1, E2 and I2 (PGE1,during revascularisation following an ischaemic in-
sult.1 The pathophysiological processes involved in PGE2, PGI2) and thromboxane A2 (TxA2) while the
leucotrienes8 include leucotriene B4 (LTB4) and thereperfusion injury are complex and unclear.2,3 Many
chemical mediators are involved, inducing cellular peptidoleucotrienes C4D4E4 (LTC4D4E4).
Iloprost is the long-acting stable analogue of pro-injury by the action of oxygen-derived free radicals
on cell membranes4 resulting in lipid peroxidation and stacyclin (PGI2). Because these compounds have im-
portant effects on the vasculature (see below) in boththe generation of vasoactive arachidonic acid de-
rivatives called eicosanoids. The term eicosanoids is the resting and disease states, many investigators have
looked at the effects of endogenously released andused to refer to all compounds derived from 20-carbon
unsaturated fatty acid precursors. These compounds exogenously administered prostaglandins in a variety
of organ- and tissue-injury models. In the currentare principally produced from the metabolism of
arachidonic acid by two pathways; lipo-oxygenation study, the effects of prostaglandin E1 and iloprost,
alone and in combination with free-radical scavengers,yields leucotrienes, and cyclo-oxygenation yields pro-
stanoids such as the prostaglandins and thromboxane and prostaglandin E2 were assessed in a rodent model
of hindlimb ischaemia–reperfusion.A2.5,6 These compounds have potent and diverse bio-
logical effects that include critical functional and struc-
tural changes to endothelial cells, myocytes, and
platelets, resulting in increased capillary permeability, Materials and Methods
oedema, and cell aggregation.7 They are produced by
Prostaglandins E1, E2 and the prostacyclin analogue
iloprost were gifts from Schering Healthcare Ltd, Bur-
* Please address all correspondence to: S. Homer-Vanniasinkam, gess Hill, W. Sussex, U.K. Bovine crystalline eryth-Vascular Surgical Unit, The General Infirmary at Leeds, Great George
Street, Leeds LS1 3EX, U.K. rocyte superoxide dismutase (SOD) and bovine hepatic
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catalase (CAT) were purchased from Sigma Chemical statistical package (SPSS Inc., U.S.A.) was used for all
analyses.Co.
Dosages: PGE1 70 ng/kg/min; PGE2: 100 ng/kg/min; Results
iloprost: 100 ng/kg/min; SOD: 35 000 IU/kg/h; cata-
lase: 400 000 IU/kg/h. 1. Gastrocnemius muscle blood flow (GMBF)
The results are shown in Table 1. All the results are
given as median values, with the interquartile range
Five groups of animals were studied: shown within brackets. The Kruskal–Wallis test
1 Rats receiving PGE1 showed significant variance between all the groups
2 Rats receiving PGE1+SOD+CAT (p<0.00001), and the Mann–Whitney U-test was also
3 Rats receiving iloprost applied for further verification.
4 Rats receiving iloprost+SOD+CAT The GMBF in the normal and control groups of
5 Rats receiving PGE2 animals at similar time points was 1.05 (0.68–1.18),
0.97 (0.79–1.13), 1.01 (0.73–1.16) and 0.08 (0.01–0.13),
0.29 (0.09–0.59), 0.05 (0.01–0.14) respectively (10, 120,
All these groups of animals underwent 6 h of uni- and 240 min). Normal animals had a PI of ap-
lateral tourniquet ischaemia followed by 4 h of re- proximately 1.0, confirming that perfusion in both
perfusion. Normal animals underwent 10 h of GA with limbs remained equal and unchanged for the duration
no tourniquet, and control groups underwent 6 h of of the experiment. In contrast, control animals ex-
ischaemia followed by 4 h of reperfusion without treat- hibited the triphasic pattern of muscle blood flow
ment. A further ischaemic group (n=10) underwent during revascularisation.
a period of 10 h ischaemia only, without a period of In animals receiving PGE1 (Fig. 1), low reflow stillreperfusion. occurred at 10 min, relative reperfusion was main-
The experimental protocol has been described pre- tained at 120 min and GMBF was increased at 240
viously.9 Briefly, anaesthetised male Sprague–Dawley min, compared with controls (p<0.01 at 240 min).
rats weighing approximately 500 g were ventilated via The addition of the free-radical scavengers SOD and
a tracheostomy. The left external jugular vein and catalase (Fig. 2) resulted in the abolition of low reflow
the left ventricle (via the right carotid artery) were (p<0.01 vs. controls at 10 min). Similar results were
cannulated. A tourniquet was applied proximally seen in the animals treated with iloprost (p<0.05 vs.
around the thigh. controls at 240 min) and iloprost in combination with
Postischaemic gastrocnemius-muscle blood flow free radical scavengers (Figs 3 and 4). In contrast, PGE2
was measured10 by injecting three separate radio- abolished low reflow at 10 min, significantly enhanced
labelled microspheres (46Sc, 85Sr, 141Ce). A perfusion perfusion at 120 min (Fig. 5), but failed to prevent
index (PI) for each time point was calculated as a ratio reperfusion injury at 240 min (vs. controls p<0.01,
of radioactive emission from the study and contra- <0.05 and NS respectively). In the ischaemic group,
lateral limbs. Muscle oedema was quantified by the muscle blood flow was virtually absent when the
wet:dry weight ratio method9 and a similar oedema tourniquet was in situ, with perfusion indices of 0.02
index was calculated. (0.00–0.04), 0.02 (0.01–0.04), and 0.04 (0.00–0.06) at 10,
The prostaglandins and free-radical scavengers were 120, and 240 min, respectively.
administered as an intravenous infusion into the left
external jugular vein. The infusion was commenced 2. Gastrocnemius muscle oedema (GMO)
30 min prior to release of the tourniquet and continued The results are shown in Table 2. All the results are
throughout the 4 h period of reperfusion. At the end given as median values, with the interquartile range
of the experiment the rats were sacrificed by overdose shown within brackets.
of i.p. pentobarbitone. Both kidneys and the ga- Muscle oedema was assessed in rats treated with
strocnemius muscles in both hindlimbs were har- PGE1 (n=10). The median oedema index was 1.42
vested. Radioactivity in these tissues and organs was (1.17–1.50). The indices in normal and control animals
measured using a Packard autogamma spectrometer. were 1.00 (0.98–1.01) and 1.23 (1.09–1.37), respectively.
Statistical analysis was carried out using the Kru- Thus infusion of PGE1 resulted in increased limb swell-
skal–Wallis test for analysis of variance and the Mann– ing (p<0.05 vs. controls). Neither 10 h of general an-
Whitney U-test, with a probability of 0.05 or less aesthesia nor ischaemia for 6 h caused significant
muscle swelling (Fig. 6).indicating statistical significance. The SPSS version 8
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Table 1. Gastrocnemius-muscle blood flow during reperfusion. Perfusion indices (median and interquartile
range). At 10 min groups E and H showed p<0.05 vs. control; D, F, and G were NS. At 120 min group H
showed p<0.01 vs. control; D, E, F, and G were NS. At 240 min groups F and G showed p<0.05 vs. control;
group D p<0.01 vs. control; group H were NS (all Mann–Whitney U-test).
Perfusion index
Study group n 10 min 120 min 240 min
A control 10 0.08 (0.01–0.13) 0.29 (0.09–0.59) 0.05 (0.01–0.14)
B normal 10 1.05 (0.68–1.18) 0.97 (0.79–1.13) 1.01 (0.73–1.16)
C ischaemia only* 10 0.02 (0.00–0.04) 0.02 (0.01–0.04) 0.04 (0.00–0.06)
D PGE1 10 0.09 (0.02–0.18) 0.33 (0.23–0.42) 0.46 (0.30–0.51)
E PGE1+SOD+CAT 10 0.44 (0.27–0.61) 0.26 (0.21–0.31) 0.39 (0.22–0.61)
F iloprost 10 0.04 (0.03–0.11) 0.16 (0.08–0.24) 0.20 (0.13–0.36)
G iloprost+SOD+CAT 10 0.38 (0.32–0.43) 0.34 (0.26–0.46) 0.29 (0.22–0.40)
H PGE2 12 0.48 (0.27–0.77) 1.04 (0.16–1.21) 0.10 (0.06–0.18)
*Matched time points of 6 h 10 min, 8 h, and 10 h respectively.
Fig. 1. Median gastrocnemius-muscle blood flow in normal animals, Fig. 3. Median gastrocnemius-muscle blood flow in normal animals,
rats receiving 6-h ischaemia but no reperfusion, and control animals rats receiving 6-h ischaemia but no reperfusion, and control animals
(6-h ischaemia and 4-h reperfusion), and rats receiving prostaglandin (6-h ischaemia and 4-h reperfusion), and rats receiving iloprost from
E1 (PGE1) from 30 min before and throughout the 4-h period of 30 min before and throughout the 4-h period of reperfusion.
reperfusion.
Fig. 4. Median gastrocnemius-muscle blood flow in normal animals,Fig. 2. Median gastrocnemius-muscle blood flow in normal animals,
rats receiving 6-h ischaemia but no reperfusion, and control animalsrats receiving 6-h ischaemia but no reperfusion, and control animals
(6-h ischaemia and 4-h reperfusion), and rats receiving iloprost and(6-h ischaemia and 4-h reperfusion), and rats receiving prostaglandin
free-radical scavengers SOD and CAT from 30 min before andE1 (PGE1) with free radical scavengers SOD and CAT from 30 min
throughout the 4-h period of reperfusion.before and throughout the 4-h period of reperfusion.
Discussion interstitial cells (fibroblasts, mast cells) and by cells in
the vascular compartment (leucocytes, platelets). They
Prostaglandins are biologically active lipid mediators have been noted to have important vasoactive actions
which could be particularly relevant to ischaemia–that are produced locally by cells within the vas-
culature (endothelium, smooth muscle, pericytes), by reperfusion: PGE1 and PGI2 induce vasodilatation,11,12
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microvascular endothelial cells from a number of sites,
including the rabbit heart and kidney20,21 and human
skin and lung.22,23
There have been previous reports of altered eico-
sanoid production following ischaemia–reperfusion
with a net decrease in vasodilator, and net increase in
vasoconstrictor compounds.24,25 Exogenous ad-
ministration of prostaglandins has been shown to in-
crease blood flow in large vessels26 as well as in the
muscle microcirculation.27,28 Whilst their role has been
studied in various organ-injury models including
myocardial, pulmonary and renal ischaemia–
reperfusion,29–31 there is little work reported in the
Fig. 5. Median gastrocnemius-muscle blood flow in normal animals, literature on the effects of exogenous administration
rats receiving 6-h ischaemia but no reperfusion, and control animals of prostaglandins on postischaemic skeletal muscle. In(6-h ischaemia and 4-h reperfusion), and rats receiving prostaglandin
this study, the effects of PGE1 and iloprost, alone andE2 (PGE2) from 30 min before and throughout the 4-h period of
reperfusion. in combination with free-radical scavengers, and PGE2,
were assessed in the rodent hindlimb ischaemia–
Table 2. Gastrocnemius muscle oedema. Oedema indices (median reperfusion model described above. The rationale for
and interquartile range). Group D p>0.05 vs. controls; groups B
combining free-radical scavengers with prostaglandinsand C NS vs. controls (Mann–Whitney U-test).
is explained below.
Study group n Oedema index The results indicate a partially beneficial role for
prostaglandins in skeletal muscle ischaemia–A control 12 1.23 (1.09–1.37)
B normal 8 1.00 (0.98–1.01) reperfusion: both PGE1 and iloprost enhanced muscle
C ischaemic 12 1.01 (0.99–1.03) blood flow at 4 h reperfusion, though in animalsD PGE1 10 1.42 (1.17–1.50)
treated with PGE1 this was associated with muscle
oedema. Neither compound abolished low reflow. This
observation prompted the addition of free-radical
scavengers, as previous work in our laboratory had
shown that these agents were able to improve blood
flow during the initial period of reperfusion.32 The
present study also confirmed a role for oxygen free
radicals in the causation of poor flow in the early
phase of muscle reperfusion. In contrast, PGE2 im-
proved muscle blood flow at 10 and 120 min re-
perfusion but failed to prevent reperfusion injury at
240 min.
A number of factors could explain the partially
Fig. 6. Median gastrocnemius-muscle oedema in normal animals, salutary role of prostaglandins in ischaemia–rats receiving 6-h ischaemia but no reperfusion, and control animals
reperfusion. Some of the beneficial effects of these(6-h ischaemia and 4-h reperfusion). Bars are interquartile ranges.
compounds have already been alluded to above. In
addition, PGE1 has been reported to inhibit neutrophilinhibit platelet and leucocyte aggregation13,14 and ex-
activation during ischaemia–reperfusion33 and to acthibit anti-inflammatory activity such as suppression
directly on the muscle microcirculation causing vaso-of tumour necrosis-factor production.15 They have also
dilatation, when applied topically to the rat cremasterbeen shown to have immunosuppressive16 and cyto-
muscle.34 This latter action of PGE1 could account forprotective effects.17 Whilst PGE2 shares some of these
the gastrocnemius-muscle oedema seen in this groupproperties, it has little inhibitory effect on platelet
of animals. A study of the effect of intra-arterial PGE1aggregation18 and its putative cytoprotective role has
on blood flow in normal and ischaemic canine hind-recently been challenged by Langer et al.,19 who
limbs showed that, whilst significant increases in skinshowed increased mucosal permeability with exo-
blood flow occurred in both groups of animals, musclegenous PGE2 in a rodent model of mesenteric isch-
perfusion increased in the normal limbs only.35 How-aemia–reperfusion. This prostaglandin, however, has
been noted to be the major eicosanoid produced by ever, in a prospective double-blind clinical study in
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11 Long WA, Rubin LJ. Prostacyclin and PGE1 treatment of pul-which thirty patients with ischaemic ulcers or rest
monary hypertension. Am Rev Respir Dis 1987; 136: 773–776.pain were randomised to receive intravenous PGE1 12 Mulvin D, Jones K, Howard R et al. The effect of prostacyclin
or placebo, there was no significant improvement in as a constituent of a preservation solution in protecting lungs
from ischemic injury because of its vasodilatory properties.symptoms or ulcer-healing in the prostaglandin-
Transplantation 1990; 49: 828–830.treated group.36 Similarly, whilst iloprost has a host of 13 Vane JR. Adventures and excursions in bioassay – the stepping
potentially beneficial actions such as vasodilatation,37 stones to prostacyclin. Postgrad Med 1983; 59: 743–758.
14 Hooper TL, Thomson DS, Jones MT et al. Amelioration ofinhibition of neutrophil-endothelial adhesion38 and sta-
lung ischemic injury with prostacyclin. Transplantation 1990; 49:bilisation of cell membranes,39 reports of the efficacy
1031–1035.
of iloprost in improving blood flow must be viewed 15 Kunkel SL, Remick DG, Spengler M, Chensue SW. Modulation
of macrophage-derived interleukin-1 and tumour necrosis factorcautiously. Campion et al. found that increased femoral
by prostaglandin E2. Adv Prostaglandin Thromboxane Leukot Resartery flow was seen when iloprost was infused intra-
1987; 17: 155–158.arterially into the femoral artery but not when it was 16 Imura M, Higashi K, Yada I et al. Effect of prostaglandin E1 on
given intravenously.26 The authors postulated that this the prolongation of rat cardiac allograft survival. Transplant Proc
1987; 19: 1312–1315.could be due to vasodilatation occurring at other sites
17 Robert A. Cytoprotection by prostaglandins. Gastroenterology(e.g. pulmonary, mesenteric, renal) with a resultant 1979; 77: 761–767.
redistribution of blood flow. Studies of skeletal muscle 18 Weeks JR, Sekhar NC, Ducharme DW. Relative activity of
prostaglandins E1, A1, E2 and A2 on lipolysis, platelet aggregation,ischaemia–reperfusion40,41 demonstrated decreased
smooth muscle and the cardiovascular system. J Pharm Pharmacolmuscle infarction in animals treated with iloprost. It
1969; 21: 103–108.
is worth noting that in these studies iloprost was 19 Langer JC, Sohal SS, Blennerhassett P. Mucosal permeability
after subclinical intestinal ischemia–reperfusion injury: an ex-administered prior to ischaemia rather than prior to
ploration of possible mechanisms. J Pediatr Surg 1995; 30: 568–572.reperfusion. In the present study, the infusion was
20 Gerritsen ME, Cheli CD. Arachidonic acid and prostaglandincommenced prior to reperfusion, since it was felt this endoperoxide metabolism in isolated rabbit coronary micro-
more closely mimicked the clinical situation in the vessels and isolated and cultivated coronary microvessel endo-
thelial cells. J Clin Invest 1983; 72: 1658–1671.management of patients with acute limb ischaemia.
21 Chaudhari A, Pedram A, Kirschenbaum MA. PGI2 is not aCurrently prostaglandins are not used routinely in major prostanoid produced by cultured rabbit renal micro-
the treatment of limb ischaemia. The results of this vascular endothelial cells. Am J Physiol 1989; 256: F266–F273.
22 Charo IF, Shak S, Karasek ME, Davidson PM, Goldstein IM.study suggest that prostaglandins could have a role
Prostaglandin I2 is not a major metabolite of arachidonic acid inin the therapeutic management of skeletal muscle
cultured endothelial cells from human foreskin microvessels. J
ischaemia–reperfusion injury. Clin Invest 1984; 74: 914–919.
23 Carley WW, Niedbala MJ, Gerritsen ME. Isolation, cultivation
and partial characterization of microvascular endothelium de-
rived from human lung. Am J Respir Cell Mol Biol 1992; 7: 914–919.
24 Feng L-J, Berger BE, Lysz TW, Shaw WW. Vasoactive prosta-
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